Status:
COMPLETED
Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®
Eligibility Criteria
Inclusion
- Participants must be 18-70 years of age
- Participants can be male or female
- Women that are able to have children must have a negative pregnancy test.
Exclusion
- Involvement in or planning of this study
- Participation in another clinical study within 28 days of this one
- For women, pregnancy or attempting to become pregnant.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00230516
Start Date
September 1 2005
End Date
February 1 2006
Last Update
January 4 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Los Angeles, California, United States
2
Research Site
Oklahoma City, Oklahoma, United States